AlphaCore Capital’s 10x Genomics TXG Stock Holding History

AlphaCore Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$200K	Buy	+2,214	New	+$130K	﹤0.01%	1298

Other funds holding TXG

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Counterpoint Mutual Funds San Diego, California $1.16B AUM 33.78% 1-Year Est. Return

AlphaCore Capital's TXG Position: Q3 2026 in Review

AlphaCore Capital opened a new position in 10x Genomics (TXG) in Q3 2026: 2,214 shares worth $200K. The stake represents ﹤0.01% of the portfolio and ranks #1298 among its holdings.

203 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

AlphaCore Capital held 2,214 shares of 10x Genomics worth $200K as of Q3 2026.
10x Genomics was a new AlphaCore Capital position in Q3 2026.
10x Genomics made up ﹤0.01% of AlphaCore Capital's portfolio in Q3 2026, its #1298 holding.
203 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on AlphaCore Capital's 13F filing for Q3 2026, filed 4 Nov 2026.